[go: up one dir, main page]

WO2001041770A3 - Nanoparticulate eplerenone compositions - Google Patents

Nanoparticulate eplerenone compositions Download PDF

Info

Publication number
WO2001041770A3
WO2001041770A3 PCT/US2000/030179 US0030179W WO0141770A3 WO 2001041770 A3 WO2001041770 A3 WO 2001041770A3 US 0030179 W US0030179 W US 0030179W WO 0141770 A3 WO0141770 A3 WO 0141770A3
Authority
WO
WIPO (PCT)
Prior art keywords
eplerenone
nanoparticulate eplerenone
compositions
eplerenone compositions
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/030179
Other languages
French (fr)
Other versions
WO2001041770A2 (en
Inventor
Shilpa S Thosar
Rajeev D Gokhale
Dwain S Tolbert
Subhash Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to AU17562/01A priority Critical patent/AU1756201A/en
Priority to AT00980277T priority patent/ATE293977T1/en
Priority to DE60019741T priority patent/DE60019741T2/en
Priority to DK00980277T priority patent/DK1175220T3/en
Priority to EP00980277A priority patent/EP1175220B1/en
Priority to HK02101220.8A priority patent/HK1039897A1/en
Publication of WO2001041770A2 publication Critical patent/WO2001041770A2/en
Publication of WO2001041770A3 publication Critical patent/WO2001041770A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided a pharmaceutical composition comprising eplerenone in solid particulate form, wherein at least 90% of the eplerenone particles are smaller than about 15 νm, for example about 0.01 to about 1 νm, in diameter. The composition can be adapted for oral administration, for example as a tablet or capsule comprising eplerenone in a unit dosage amount of about 10 to about 1000 mg and one or more excipients.
PCT/US2000/030179 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions Ceased WO2001041770A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU17562/01A AU1756201A (en) 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions
AT00980277T ATE293977T1 (en) 1999-12-08 2000-12-04 NANOPARTICLE COMPOSITIONS CONTAINING EPLERENONE
DE60019741T DE60019741T2 (en) 1999-12-08 2000-12-04 NANOPARTICLE COMPOSITIONS CONTAINING EPLERENONE
DK00980277T DK1175220T3 (en) 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions
EP00980277A EP1175220B1 (en) 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions
HK02101220.8A HK1039897A1 (en) 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16965899P 1999-12-08 1999-12-08
US60/169,658 1999-12-08
US20898100P 2000-06-02 2000-06-02
US60/208,981 2000-06-02

Publications (2)

Publication Number Publication Date
WO2001041770A2 WO2001041770A2 (en) 2001-06-14
WO2001041770A3 true WO2001041770A3 (en) 2001-11-22

Family

ID=26865266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030179 Ceased WO2001041770A2 (en) 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions

Country Status (13)

Country Link
US (2) US20020006919A1 (en)
EP (1) EP1175220B1 (en)
AR (1) AR026745A1 (en)
AT (1) ATE293977T1 (en)
AU (1) AU1756201A (en)
CO (1) CO5251419A1 (en)
DE (1) DE60019741T2 (en)
DK (1) DK1175220T3 (en)
ES (1) ES2240209T3 (en)
HK (1) HK1039897A1 (en)
PE (1) PE20010910A1 (en)
PT (1) PT1175220E (en)
WO (1) WO2001041770A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (en) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CZ305202B6 (en) 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Pharmaceutical composition
RU2356550C2 (en) * 2001-01-26 2009-05-27 Шеринг Корпорейшн Combined activator (activators) of receptor activated with peroxise proliferator (rapp), and sterol absorption inhibitor (inhibitors) and treatment of vessel diseases
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6908626B2 (en) * 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
DE10164510A1 (en) * 2001-12-20 2003-07-10 Schering Ag Oral Fludara pure formulation with rapid release of the active ingredient
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
AR040588A1 (en) * 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
BR0215979A (en) * 2002-12-13 2005-11-01 Jagotec Ag Formulation of topical nanoparticulate spironolactone, use of spironolactone nanosuspensions, crystal lattice system, and process for preparing a topical nanoparticulate spironolactone formulation
MXPA05009502A (en) 2003-03-07 2005-10-18 Schering Corp Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia.
JP4589919B2 (en) * 2003-03-07 2010-12-01 シェーリング コーポレイション Substituted azetidinone compounds, their formulations and uses for the treatment of hypercholesterolemia
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
EP1948137A2 (en) * 2005-11-10 2008-07-30 Wyeth a Corporation of the State of Delaware Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-(2-hydroxyethyl)(methylsulfonyl) amino-n-methyl-1-benzofuran-3-carboxamide and method of making same
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080181958A1 (en) * 2006-06-19 2008-07-31 Rothrock Ginger D Nanoparticle fabrication methods, systems, and materials
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008027571A2 (en) * 2006-08-30 2008-03-06 Liquidia Technologies, Inc. Nanoparticles having functional additives for self and directed assembly and methods of fabricating same
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
AU2007335192A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
ATE554751T1 (en) * 2007-07-13 2012-05-15 Bend Res Inc NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSE POLYMER
US9082409B2 (en) * 2008-08-28 2015-07-14 Avaya Inc. Binary-caching for XML documents with embedded executable code
EP2201977A1 (en) * 2008-12-23 2010-06-30 Siegfried Generics International AG Metering device for creating a gas flow with an active agent
US20110268775A1 (en) * 2009-01-06 2011-11-03 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
TR201007653A2 (en) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Pharmaceutical composition containing eplerenone
US9849255B2 (en) 2011-11-25 2017-12-26 Mahmut Bilgic Inhalation device
CN103263398B (en) * 2013-06-06 2014-05-14 山东罗欣药业股份有限公司 Cefdinir composition capsule and preparation method thereof
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN109925293B (en) * 2019-03-15 2022-02-01 南京卡文迪许生物工程技术有限公司 Eplerenone oral solid preparation and preparation method thereof
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
JP2024523520A (en) 2021-06-25 2024-06-28 ニコベンチャーズ トレーディング リミテッド Oral Products and Methods of Manufacturing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122232A1 (en) * 1983-04-13 1984-10-17 Ciba-Geigy Ag 20-Spiroxanes and analogues with open ring E, process for their preparation and pharmaceutical compositions
WO1995015166A1 (en) * 1993-12-02 1995-06-08 Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
WO2000033847A1 (en) * 1998-12-09 2000-06-15 G.D. Searle & Co. Micronized eplerenone compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122232A1 (en) * 1983-04-13 1984-10-17 Ciba-Geigy Ag 20-Spiroxanes and analogues with open ring E, process for their preparation and pharmaceutical compositions
WO1995015166A1 (en) * 1993-12-02 1995-06-08 Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
WO2000033847A1 (en) * 1998-12-09 2000-06-15 G.D. Searle & Co. Micronized eplerenone compositions

Also Published As

Publication number Publication date
ES2240209T3 (en) 2005-10-16
PT1175220E (en) 2005-07-29
US20030212053A1 (en) 2003-11-13
DK1175220T3 (en) 2005-08-29
PE20010910A1 (en) 2001-09-10
DE60019741T2 (en) 2006-03-02
EP1175220B1 (en) 2005-04-27
AU1756201A (en) 2001-06-18
CO5251419A1 (en) 2003-02-28
US20020006919A1 (en) 2002-01-17
WO2001041770A2 (en) 2001-06-14
AR026745A1 (en) 2003-02-26
HK1039897A1 (en) 2002-05-17
EP1175220A2 (en) 2002-01-30
DE60019741D1 (en) 2005-06-02
ATE293977T1 (en) 2005-05-15

Similar Documents

Publication Publication Date Title
WO2001041770A3 (en) Nanoparticulate eplerenone compositions
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
CA2385890A1 (en) Controlled release compositions comprising nimesulide
EP1275381A4 (en) Time-release coated solid compositions for oral administration
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
EA200600884A1 (en) COMPOSITION COMPLEXES EXTROGEN-CYCLODEXTRIN
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
CA2388609A1 (en) Oxcarbazepine formulations for administration with or without food
HUP0004966A2 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
EP1131050B8 (en) Galenic formulations fast disintegrating in the mouth and method for preparing same
CA2419993A1 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
BG102857A (en) Antimycotic substance-containing and acetate buffer-containing compositions
PT1411921E (en) Pharmaceutical compositions containing terbinafine and use thereof
WO2002024203A3 (en) Controlled release formulations for oral administration
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
RU2003100507A (en) PHARMACEUTICAL COMPOSITIONS
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride
AU1515595A (en) Method for preparing low dose pharmaceutical products
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
CA2382426A1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
YU81101A (en) Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
AU4137300A (en) Stable solid pharmaceutical compositions containing enalapril maleate
AU1240800A (en) Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000980277

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000980277

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2000980277

Country of ref document: EP